Dutasterida + Tansulosina Alter Genéricos 0.5 mg + 0.4 mg Cápsula Португалія - португальська - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

dutasterida + tansulosina alter genéricos 0.5 mg + 0.4 mg cápsula

alter genéricos - comercialização de produtos genéricos, lda. - dutasterida + tansulosina - cápsula - 0.5 mg + 0.4 mg - dutasterida 0.5 mg ; tansulosina, cloridrato 0.4 mg - tamsulosin and dutasteride - genérico - duração do tratamento: longa duração

Orgovyx Європейський Союз - португальська - EMA (European Medicines Agency)

orgovyx

accord healthcare s.l.u. - relugolix - neoplasias prostáticas - terapia endócrina - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Tansulosina Sandoz 0.4 mg Comprimido de libertação prolongada Португалія - португальська - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

tansulosina sandoz 0.4 mg comprimido de libertação prolongada

sandoz farmacêutica, lda. - tansulosina - comprimido de libertação prolongada - 0.4 mg - tansulosina, cloridrato 0.4 mg - tamsulosin - genérico - duração do tratamento: longa duração

Sarix 0.5 mg + 0.4 mg Cápsula Португалія - португальська - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

sarix 0.5 mg + 0.4 mg cápsula

laboratórios atral, s.a. - dutasterida + tansulosina - cápsula - 0.5 mg + 0.4 mg - dutasterida 0.5 mg ; tansulosina, cloridrato 0.4 mg - tamsulosin and dutasteride - n/a - duração do tratamento: longa duração

Sarix 0.5 mg + 0.4 mg Cápsula Португалія - португальська - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

sarix 0.5 mg + 0.4 mg cápsula

laboratórios atral, s.a. - dutasterida + tansulosina - cápsula - 0.5 mg + 0.4 mg - dutasterida 0.5 mg ; tansulosina, cloridrato 0.4 mg - tamsulosin and dutasteride - n/a - duração do tratamento: longa duração

Nubeqa Європейський Союз - португальська - EMA (European Medicines Agency)

nubeqa

bayer ag - darolutamide - prostática benigna neoplasias, a castração-resistente - terapia endócrina - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

Akeega Європейський Союз - португальська - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostática benigna neoplasias, a castração-resistente - agentes antineoplásicos - treatment of adult patients with prostate cancer.

Abiraterone Accord Європейський Союз - португальська - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - acetato de abiraterona - neoplasias prostáticas - terapia endócrina - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Mylan Європейський Союз - португальська - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - acetato de abiraterona - neoplasias prostáticas - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka Європейський Союз - португальська - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - acetato de abiraterona - neoplasias prostáticas - terapia endócrina - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.